Dr. Weimin Tang is EVP of I-Mab Biopharma, a clinical stage biotech company focusing on immunology and oncology. He served as Interim CEO/Head of US Business Development at Jiangsu Hengrui Medicine previously and build Hengrui’s US business development team and clinical operation in Princeton, NJ. He was trained as a cancer biologist with a PhD in Biochemistry from Rutgers University. He has accumulated more than 20 years of research and business management experience with global pharmaceutical and biotech companies, such as Synaptic Pharmaceutical, BMS, JNJ, Sanofi, American Cyanamid, ACrown Biosciences, Hengrui Medicine and I-Mab Biopharma. Through his industry career, he expanded his function from basic biology to high throughput screening, DMPK, clinical development and business management. Dr. Tang received his bachelor’s degree from Zhejiang University and master’s degree from Chinese Academy of Sciences.

© 2024 BioFutureTM. All Rights Reserved

Produced by